evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,125 questions · 1,173 findings · 91 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 192 · 16.4%GRADE not reported 47 · 4%Very low 199 · 17%Low 325 · 27.7%Moderate 271 · 23.1%High 139 · 11.8%

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

Hand‐foot syndrome · patients with early breast cancer

Capecitabine‐containing regimens probably leads to higher hand‐foot syndrome compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine

OS: hormone receptor‐negativemedian · people with metastatic breast cancer

Capecitabine‐containing regimens showed no clear difference in OS: hormone receptor‐negativemedian compared with chemotherapy regimens without capecitabine (high certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine

Progression‐free survival · people with metastatic breast cancer

Capecitabine‐containing regimens probably leads to lower progression‐free survival (PFS)median compared with chemotherapy regimens without capecitabine (moderate certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine

PFS: hormone receptor‐positivemedian · people with metastatic breast cancer

Capecitabine‐containing regimens probably leads to lower PFS: hormone receptor‐positivemedian compared with chemotherapy regimens without capecitabine (moderate certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine

PFS: hormone receptor‐negativemedian · people with metastatic breast cancer

Capecitabine‐containing regimens showed no clear difference in PFS: hormone receptor‐negativemedian compared with chemotherapy regimens without capecitabine (moderate certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine

Objective response rate · people with metastatic breast cancer

Capecitabine‐containing regimens showed no clear difference in objective response rate compared with chemotherapy regimens without capecitabine (moderate certainty).

1 finding from 1 review

Carboplatin vs cisplatin chemotherapy

Overall survival (baseline risks for low‐ and high‐risk groups in the control arm were estimated at 1 year) · combination with third‐generation drugs for advanced non‐small cell lung cancer

Carboplatin showed no clear difference in overall survival (baseline risks for low‐ and high‐risk groups in… compared with cisplatin chemotherapy (high certainty).

1 finding from 1 review

Carboplatin vs cisplatin chemotherapy

Adverse events: neurotoxicity (grade 3/4) ( · combination with third‐generation drugs for advanced non‐small cell lung cancer

Carboplatin probably leads to higher grade III or IV neurotoxicity compared with cisplatin chemotherapy (moderate certainty).

1 finding from 1 review

Carboplatin vs cisplatin chemotherapy

Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · combination with third‐generation drugs for advanced non‐small cell lung cancer

Carboplatin probably leads to higher grade III or IV thrombocytopenia compared with cisplatin chemotherapy (moderate certainty).

1 finding from 1 review

Carboplatin vs cisplatin chemotherapy

Grade III or IV renal toxicity · combination with third‐generation drugs for advanced non‐small cell lung cancer

Carboplatin showed no clear difference in grade III or IV renal toxicity compared with cisplatin chemotherapy (moderate certainty).

1 finding from 1 review

Chemmotherapy combined with biological therapy vs chemotherapy alone

Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma

Chemmotherapy combined with biological therapy showed no clear difference in overall survival compared with chemotherapy (moderate certainty).

1 finding from 1 review

Chemmotherapy combined with biological therapy vs chemotherapy alone

Progression‐free survival · advanced gastric and oesophago‐gastric junction adenocarcinoma

It is very uncertain whether chemmotherapy combined with biological therapy changes progression‐free survival compared with chemotherapy (very low certainty).

1 finding from 1 review

Chemmotherapy combined with biological therapy vs chemotherapy alone

Serious adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma

It is very uncertain whether chemmotherapy combined with biological therapy changes serious adverse events compared with chemotherapy (very low certainty).

1 finding from 1 review

Chemmotherapy combined with biological therapy vs chemotherapy alone

Tumour response · advanced gastric and oesophago‐gastric junction adenocarcinoma

It is very uncertain whether chemmotherapy combined with biological therapy changes tumour response rate compared with chemotherapy (very low certainty).

1 finding from 1 review

Chemmotherapy combined with biological therapy vs chemotherapy alone

Any adverse events · advanced gastric and oesophago‐gastric junction adenocarcinoma

Chemmotherapy combined with biological therapy showed no clear difference in any adverse events compared with chemotherapy (moderate certainty).

1 finding from 1 review

Summary of Findings Table ‐ Antithrombin concentrates vs no antithrombin concentrates

Death Analysis 1.1 · adults with acute lymphoblastic leukaemia treated with asparaginase‐based chemotherapy

It is very uncertain whether summary of Findings Table ‐ Antithrombin concentrates changes all‐cause mortality ‐ Intention‐to‐treat analysis compared with no antithrombin concentrates (very low certainty).

1 finding from 1 review